Emerging therapies in chronic spontaneous urticaria

Taek Ki Min, Sarbjit S. Saini

Research output: Contribution to journalReview articlepeer-review

Abstract

Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU.

Original languageEnglish (US)
Pages (from-to)470-481
Number of pages12
JournalAllergy, Asthma and Immunology Research
Volume11
Issue number4
DOIs
StatePublished - Jul 2019

Keywords

  • Biologics
  • Chronic urticaria
  • Pathophysiology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Emerging therapies in chronic spontaneous urticaria'. Together they form a unique fingerprint.

Cite this